By Fineline Cube 
The National Medical Products Administration (NMPA) approved Geneseeq Technology Inc.‘s (a genetic cancer testing service provider operating in Canada and China) Fandekang NTRK1/2/3 gene fusion detection kit as a companion diagnostic (CDx) for eratrectinib, a next‑generation highly selective TRK inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd.
Approval Overview
| Item | Detail |
|---|---|
| Regulatory Agency | NMPA (China) |
| Product Approved | Fandekang NTRK1/2/3 gene fusion detection kit |
| Approval Type | Companion diagnostic (CDx) |
| Companion Drug | Eratrectinib — next‑generation highly selective TRK inhibitor |
| Drug Developer | Jiangsu Vcare PharmaTech Co., Ltd. |
| CDx Developer | Geneseeq Technology Inc. (operating in Canada and China) |
| Approval Date | 6 Aug 2026 |
Diagnostic Profile
- Detection Challenge Addressed: As the original CDx for eratrectinib, Fandekang addresses key detection challenges including the broad cross‑tumor distribution, low incidence, and complex fusion patterns of NTRK1/2/3 fusions.
- Cross‑Tumor Capability: Enables accurate identification of NTRK fusion variants across different cancer types — critical for a tumor‑agnostic therapy like a TRK inhibitor.
- Clinical Consistency Validated: Bridging studies demonstrated that patients who tested positive by Fandekang achieved objective response rates in both treatment‑naïve and previously treated populations that were highly consistent with drug clinical trial results.
Drug Context & Partnership
- Drug Approval: Vcare’s eratrectinib was approved this June for the treatment of adult and adolescent (aged 12 and above) patients with solid tumors harboring NTRK fusion genes.
- Long‑Standing Collaboration: Vcare PharmaTech and Geneseeq have a long‑standing collaborative relationship, with the CDx developed in parallel with the drug — a model that supports synchronized approval and clinical deployment.
- Tumor‑Agnostic Pairing: The CDx approval completes the drug‑diagnostic pairing needed to identify eligible patients across tumor types under the tumor‑agnostic indication.
Market Impact & Outlook
- Precision Oncology Infrastructure: NTRK fusions occur at low frequency across a wide range of solid tumors, making reliable pan‑cancer detection essential — Fandekang’s approval strengthens China’s precision oncology testing infrastructure.
- TRK Inhibitor Competition: Eratrectinib enters the TRK inhibitor market alongside established agents, with diagnostic accuracy and patient identification becoming key competitive differentiators.
- Cross‑Border Diagnostic Player: Geneseeq’s dual Canada‑China operating footprint positions it to pursue CDx opportunities across both regulated markets.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding diagnostic adoption and clinical deployment of Fandekang alongside eratrectinib. Actual results may differ due to risks including hospital adoption, reimbursement, and testing volume uptake.-Fineline Info & Tech